Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04421027 · OUTCOME

Time to Definitive Extubation

A Study of Baricitinib (LY3009104) in Participants With COVID-19 · Source last updated 2022-07-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
95% Confidence Interval
Time frame
Day 1 to Day 28

What was measured

Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.

Analysis population: All participants randomly assigned to study intervention who were intubated at some point during the study.

Groups in this outcome

Placebo + SOC

Placebo administered orally QD with standard of care.

Baricitinib + SOC

4 mg baricitinib administered orally QD with standard of care.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo + SOC136
Baricitinib + SOC125

Reported measurements

Source class 1
Values in days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Placebo + SOCNANot reportedNANAMedian not evaluable due to less than half the participants meeting criteria.
Baricitinib + SOCNANot reportedNANAMedian not evaluable due to less than half the participants meeting criteria.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Median not evaluable due to less than half the participants meeting criteria.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      2. comment
        Median not evaluable due to less than half the participants meeting criteria.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      136
    2. group Id
      OG001
      value
      125
    units
    Participants
description
Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.
dispersion Type
95% Confidence Interval
groups
  1. description
    Placebo administered orally QD with standard of care.
    id
    OG000
    title
    Placebo + SOC
  2. description
    4 mg baricitinib administered orally QD with standard of care.
    id
    OG001
    title
    Baricitinib + SOC
param Type
MEDIAN
population Description
All participants randomly assigned to study intervention who were intubated at some point during the study.
reporting Status
POSTED
time Frame
Day 1 to Day 28
title
Time to Definitive Extubation
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice